FDA Approves Infilbray for Type 3 Gaucher Disease

The oral venglustat treatment targets neurological symptoms of a rare lysosomal storage disorder, while the European Commission clears a new rabies vaccine.

Updated on Nov. 19, 2026 in Biotech

FDA Approves Infilbray for Type 3 Gaucher Disease

Live Poll

Do you trust new vaccines and drugs approved by regulators to be safe?

The U.S. Food and Drug Administration approved Infilbray (venglustat), an oral glucosylceramide synthase inhibitor, for neurological manifestations of Type 3 Gaucher disease. In the same week, the European Commission approved Sanofi's VaxRabeo rabies vaccine for pre-exposure and post-exposure prophylaxis across all age groups.

Why it matters

Infilbray is designed to act across the blood-brain barrier, addressing central nervous system symptoms of a rare disorder that current enzyme replacement therapy does not treat effectively. VaxRabeo's approval adds to global rabies prevention efforts against a disease that causes roughly 59,000 deaths worldwide each year.

The approval rests on the LEAP2MONO Phase 3 study, which compared Infilbray against imiglucerase in patients aged 12 and older with neurological manifestations of Type 3 Gaucher disease. The source does not provide the effect size or the study's follow-up duration.

The players

Sanofi

A French multinational pharmaceutical company headquartered in Paris that develops treatments across rare diseases, vaccines and other therapeutic areas.

The details

Infilbray is a novel oral glucosylceramide synthase inhibitor that acts across the blood-brain barrier, and it demonstrated improvements in neurological manifestations over imiglucerase. VaxRabeo, an inactivated Wistar-strain rabies vaccine made using Vero-cell technology, matched existing vaccines in protective antibody levels, immunogenicity and safety, with improved thermostability and a longer shelf life.

Timeline

  1. Wednesday: FDA approval of Infilbray and European Commission approval of VaxRabeo were announced.

  2. Thursday: Sanofi shares fell 2.08% to $46.14 in premarket trading.

Treatment Landscape

Infilbray extends beyond the enzyme replacement therapy imiglucerase, the long-standing standard for Gaucher disease, by targeting neurological manifestations that the infusion-based therapy does not reach. Its oral, brain-penetrant design marks a departure from the intravenous approach that has defined treatment for this rare lysosomal storage disorder.

For people living with Type 3 Gaucher disease, an oral option that reaches neurological symptoms could change treatment conversations with their care teams. The approval may also expand access to rabies pre-exposure and post-exposure protection in regions where the disease remains present.

The takeaway

Approvals for both a rare-disease therapy and a widely used vaccine show regulators advancing treatments that address long-unmet needs. Readers following either condition should track how these products reach clinics and patients in the months ahead.

Further reading

Explore more biotech developments shaping treatments for rare diseases and vaccines worldwide.

Source note: This article includes information reported by Benzinga.

Live Poll

Do you trust new vaccines and drugs approved by regulators to be safe?